3D Medicines Inc. (HKG:1244)

3D Medicines Statistics

Total Valuation

3D Medicines has a market cap or net worth of HKD 920.19 million. The enterprise value is 545.20 million.

Market Cap	920.19M
Enterprise Value	545.20M

Important Dates

The last earnings date was Tuesday, March 31, 2026.

Earnings Date	Mar 31, 2026
Ex-Dividend Date	n/a

Share Statistics

3D Medicines has 245.39 million shares outstanding. The number of shares has increased by 0.22% in one year.

Current Share Class	245.39M
Shares Outstanding	245.39M
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	+0.33%
Owned by Insiders (%)	14.83%
Owned by Institutions (%)	2.28%
Float	172.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.32
PB Ratio	1.52
P/TBV Ratio	1.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.76
EV / Sales	1.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.28.

Current Ratio	1.45
Quick Ratio	1.19
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-39.46

Financial Efficiency

Return on equity (ROE) is -29.62% and return on invested capital (ROIC) is -15.74%.

Return on Equity (ROE)	-29.62%
Return on Assets (ROA)	-11.98%
Return on Invested Capital (ROIC)	-15.74%
Return on Capital Employed (ROCE)	-37.43%
Weighted Average Cost of Capital (WACC)	5.25%
Revenue Per Employee	2.17M
Profits Per Employee	-1.08M
Employee Count	183
Asset Turnover	0.33
Inventory Turnover	15.10

Taxes

Income Tax	-61,205
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.65% in the last 52 weeks. The beta is 0.27, so 3D Medicines's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+9.65%
50-Day Moving Average	4.06
200-Day Moving Average	5.68
Relative Strength Index (RSI)	42.93
Average Volume (20 Days)	92,334

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 3D Medicines had revenue of HKD 396.26 million and -197.56 million in losses. Loss per share was -0.80.

Revenue	396.26M
Gross Profit	332.69M
Operating Income	-229.62M
Pretax Income	-205.81M
Net Income	-197.56M
EBITDA	-219.71M
EBIT	-229.62M
Loss Per Share	-0.80

Balance Sheet

The company has 487.31 million in cash and 170.02 million in debt, with a net cash position of 317.29 million or 1.29 per share.

Cash & Cash Equivalents	487.31M
Total Debt	170.02M
Net Cash	317.29M
Net Cash Per Share	1.29
Equity (Book Value)	606.34M
Book Value Per Share	2.70
Working Capital	191.75M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	10.23M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 83.96%, with operating and profit margins of -57.95% and -49.86%.

Gross Margin	83.96%
Operating Margin	-57.95%
Pretax Margin	-51.94%
Profit Margin	-49.86%
EBITDA Margin	-55.45%
EBIT Margin	-57.95%
FCF Margin	n/a

Dividends & Yields

3D Medicines does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.22%
Shareholder Yield	-0.22%
Earnings Yield	-21.47%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1